Abstract
To develop new vaccines for the treatment of patients with cancer, target antigens presented on tumor cell surfaces have been cloned. Many of these antigens are non-mutated differentiation antigens and are expressed by virtually all melanomas, making them attractive components for a widely efficacious melanoma vaccine. These antigens are also expressed by melanocytes, however, and are likely to be subject to immune tolerance. A central challenge for tumor immunologists has thus been the breaking of tolerance to cancer antigens. We review recent clinical trials using experimental cancer vaccines, including recent evidence that therapeutic vaccines can induce objective responses in patients with metastatic malignant melanoma. We focus on the foundations of these approaches in new experimental animal models designed to test novel vaccines and report on what these new models predict for the future development of therapeutic vaccines for cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 50-57 |
| Number of pages | 8 |
| Journal | Current Opinion in Oncology |
| Volume | 11 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1999 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
Cite this
Developing recombinant and synthetic vaccines for the treatment of melanoma. / Restifo, Nicholas P.; Rosenberg, Steven A.
In: Current Opinion in Oncology, Vol. 11, No. 1, 1999, p. 50-57.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Developing recombinant and synthetic vaccines for the treatment of melanoma
AU - Restifo, Nicholas P.
AU - Rosenberg, Steven A.
PY - 1999
Y1 - 1999
N2 - To develop new vaccines for the treatment of patients with cancer, target antigens presented on tumor cell surfaces have been cloned. Many of these antigens are non-mutated differentiation antigens and are expressed by virtually all melanomas, making them attractive components for a widely efficacious melanoma vaccine. These antigens are also expressed by melanocytes, however, and are likely to be subject to immune tolerance. A central challenge for tumor immunologists has thus been the breaking of tolerance to cancer antigens. We review recent clinical trials using experimental cancer vaccines, including recent evidence that therapeutic vaccines can induce objective responses in patients with metastatic malignant melanoma. We focus on the foundations of these approaches in new experimental animal models designed to test novel vaccines and report on what these new models predict for the future development of therapeutic vaccines for cancer.
AB - To develop new vaccines for the treatment of patients with cancer, target antigens presented on tumor cell surfaces have been cloned. Many of these antigens are non-mutated differentiation antigens and are expressed by virtually all melanomas, making them attractive components for a widely efficacious melanoma vaccine. These antigens are also expressed by melanocytes, however, and are likely to be subject to immune tolerance. A central challenge for tumor immunologists has thus been the breaking of tolerance to cancer antigens. We review recent clinical trials using experimental cancer vaccines, including recent evidence that therapeutic vaccines can induce objective responses in patients with metastatic malignant melanoma. We focus on the foundations of these approaches in new experimental animal models designed to test novel vaccines and report on what these new models predict for the future development of therapeutic vaccines for cancer.
UR - http://www.scopus.com/inward/record.url?scp=0033002264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033002264&partnerID=8YFLogxK
U2 - 10.1097/00001622-199901000-00012
DO - 10.1097/00001622-199901000-00012
M3 - Article
C2 - 9914879
AN - SCOPUS:0033002264
VL - 11
SP - 50
EP - 57
JO - Current Opinion in Oncology
JF - Current Opinion in Oncology
SN - 1040-8746
IS - 1
ER -